Tags

Type your tag names separated by a space and hit enter

Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers.
Travel Med Infect Dis. 2014 Nov-Dec; 12(6 Pt B):726-32.TM

Abstract

BACKGROUND

Chemoprophylaxis against falciparum malaria is recommended for travellers from non-endemic countries to malarious destinations, but debate continues on benefit, especially with regard to mefloquine. Quantification of benefit for travellers from the United Kingdom (UK) was modelled to assist clinical and public health decision making.

METHODS

The model was constructed utilising: World Tourism Organization data showing total number of arrivals from the UK in countries with moderate or high malaria risk; data from a retrospective UK Clinical Practice Research Datalink (CPRD) drug utilisation study; additional information on chemoprophylaxis, case fatality and tolerability were derived from the travel medicine literature. Chemoprophylaxis with the following agents was considered: atovaquone-proguanil (AP), chloroquine with and without proguanil (C ± P), doxycycline (Dx), mefloquine (Mq). The model was validated for the most recent year with temporally matched datasets for UK travel destinations and imported malaria (2007) against UK Health Protection Agency data on imported malaria.

RESULTS

The median (mean) duration of chemoprophylaxis for each agent in weeks (CPRD) was: AP 3.3 (3.5), C ± P 9 (12.1), Dx 8 (10.3), Mq 9 (12.3): the maximum duration of use of all regimens was 52 weeks. The model correctly predicted falciparum malaria deaths and gave a robust estimate of total cases--model: 5 deaths from 1118 cases; UK Health Protection Agency: 5 deaths from 1153 cases. The number needed to take chemoprophylaxis (NNP) to prevent a case of malaria considered against the 'background' reported incidence in non-users of chemoprophylaxis deemed in need of chemoprophylaxis was: C ± P 272, Dx 269, Mq 260, AP 252; the NNP to prevent a UK traveller malaria death was: C ± P 62613, Dx 61923, Mq 59973, AP 58059; increasing the 'background' rate by 50% yielded NNPs of: C ± P 176, Dx 175, Mq 171, AP 168. The impact of substituting atovaquone-proguanil for all mefloquine usage resulted in a 2.3% decrease in estimated infections. The number of travellers experiencing moderate adverse events (AE) or those requiring medical attention or drug withdrawal per case prevented is as follows: C ± P 170, Mq 146, Dx 114, AP 103.

CONCLUSIONS

The model correctly predicted the number of malaria deaths, providing a robust and reliable estimate of the number of imported malaria cases in the UK, and giving a measure of benefit derived from chemoprophylaxis use against the likely adverse events generated. Overall numbers needed to prevent a malaria infection are comparable among the four options and are sensitive to changes in the background infection rates. Only a limited impact on the number of infections can be expected if Mq is substituted by AP.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25443997

Citation

Toovey, Stephen, et al. "Comparative Benefit of Malaria Chemoprophylaxis Modelled in United Kingdom Travellers." Travel Medicine and Infectious Disease, vol. 12, no. 6 Pt B, 2014, pp. 726-32.
Toovey S, Nieforth K, Smith P, et al. Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. Travel Med Infect Dis. 2014;12(6 Pt B):726-32.
Toovey, S., Nieforth, K., Smith, P., Schlagenhauf, P., Adamcova, M., Tatt, I., Tomianovic, D., & Schnetzler, G. (2014). Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. Travel Medicine and Infectious Disease, 12(6 Pt B), 726-32.
Toovey S, et al. Comparative Benefit of Malaria Chemoprophylaxis Modelled in United Kingdom Travellers. Travel Med Infect Dis. 2014 Nov-Dec;12(6 Pt B):726-32. PubMed PMID: 25443997.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers. AU - Toovey,Stephen, AU - Nieforth,Keith, AU - Smith,Patrick, AU - Schlagenhauf,Patricia, AU - Adamcova,Miriam, AU - Tatt,Iain, AU - Tomianovic,Danitza, AU - Schnetzler,Gabriel, PY - 2014/03/06/received PY - 2014/07/30/revised PY - 2014/08/07/accepted PY - 2014/12/3/entrez PY - 2014/12/3/pubmed PY - 2015/9/9/medline SP - 726 EP - 32 JF - Travel medicine and infectious disease JO - Travel Med Infect Dis VL - 12 IS - 6 Pt B N2 - BACKGROUND: Chemoprophylaxis against falciparum malaria is recommended for travellers from non-endemic countries to malarious destinations, but debate continues on benefit, especially with regard to mefloquine. Quantification of benefit for travellers from the United Kingdom (UK) was modelled to assist clinical and public health decision making. METHODS: The model was constructed utilising: World Tourism Organization data showing total number of arrivals from the UK in countries with moderate or high malaria risk; data from a retrospective UK Clinical Practice Research Datalink (CPRD) drug utilisation study; additional information on chemoprophylaxis, case fatality and tolerability were derived from the travel medicine literature. Chemoprophylaxis with the following agents was considered: atovaquone-proguanil (AP), chloroquine with and without proguanil (C ± P), doxycycline (Dx), mefloquine (Mq). The model was validated for the most recent year with temporally matched datasets for UK travel destinations and imported malaria (2007) against UK Health Protection Agency data on imported malaria. RESULTS: The median (mean) duration of chemoprophylaxis for each agent in weeks (CPRD) was: AP 3.3 (3.5), C ± P 9 (12.1), Dx 8 (10.3), Mq 9 (12.3): the maximum duration of use of all regimens was 52 weeks. The model correctly predicted falciparum malaria deaths and gave a robust estimate of total cases--model: 5 deaths from 1118 cases; UK Health Protection Agency: 5 deaths from 1153 cases. The number needed to take chemoprophylaxis (NNP) to prevent a case of malaria considered against the 'background' reported incidence in non-users of chemoprophylaxis deemed in need of chemoprophylaxis was: C ± P 272, Dx 269, Mq 260, AP 252; the NNP to prevent a UK traveller malaria death was: C ± P 62613, Dx 61923, Mq 59973, AP 58059; increasing the 'background' rate by 50% yielded NNPs of: C ± P 176, Dx 175, Mq 171, AP 168. The impact of substituting atovaquone-proguanil for all mefloquine usage resulted in a 2.3% decrease in estimated infections. The number of travellers experiencing moderate adverse events (AE) or those requiring medical attention or drug withdrawal per case prevented is as follows: C ± P 170, Mq 146, Dx 114, AP 103. CONCLUSIONS: The model correctly predicted the number of malaria deaths, providing a robust and reliable estimate of the number of imported malaria cases in the UK, and giving a measure of benefit derived from chemoprophylaxis use against the likely adverse events generated. Overall numbers needed to prevent a malaria infection are comparable among the four options and are sensitive to changes in the background infection rates. Only a limited impact on the number of infections can be expected if Mq is substituted by AP. SN - 1873-0442 UR - https://www.unboundmedicine.com/medline/citation/25443997/Comparative_benefit_of_malaria_chemoprophylaxis_modelled_in_United_Kingdom_travellers_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1477-8939(14)00157-4 DB - PRIME DP - Unbound Medicine ER -